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Objective: Obesity and obstructive sleep apnea in children have been associated with 
metabolic morbidities. The present study aimed to evaluate the presence of metabolic 
alterations among obese children recruited from the community, with and without obstructive 
sleep apnea syndrome (OSAS), and the impact of treatment of OSAS on metabolic profiles. 
Methods: A cross-sectional, prospective, multicenter study of Spanish children aged 3-14 
years with a body mass index (BMI) ≥95th percentile for age and sex were randomly selected 
in the first phase. Four groups emerged for follow-up: (1) no treatment; (2) dietary 
intervention; (3) surgical treatment of OSA; and (4) continuous positive airway pressure 
(CPAP) treatment of OSA. Fasting blood tests were prformed at baseline (T0) and 
approximately 1 year after the intervention (T1). 
Results: A total of 113 obese children with a mean age of 11.3±2.9 years completed T0 and 
T1 assessments. Their mean BMI z-score at T1 was 1.34±0.59, and mean Respiratory 
Disturbance Index was 8.6±13.0 at T0 and 3.3±4.0/hour t tal sleep time at T1. Only glucose 
fasting levels differed among metabolic parameters in obese children with OSAS and without 
OSAS at baseline (T0) (p=0.018). There were statistically significant diferences between 
surgically treated OSAS (p=0.002), and CPAP-treated OSAS (p=0.024) versus the non-
OSAS group in the glucose levels between baseline (T0) and follow-up (T1) after controlling 
for age and change in BMI. Significant univariate associations between BMI and C-reactive 
protein, insulin, and homeostasis model assessment of i sulin resistance emerged at both T0 
and T1. 
Conclusions: Concurrent obesity and OSAS could promote metabolic and inflammatory 

























AASM  American Association of Sleep Medicine 
AHI   Apnea-Hypopnea Index 
BMI   Body Mass Index 
OSAS   Obstructive Sleep Apnea Syndrome 
CRP   C Reactive Protein 
CPAP   Continuous Positive Airway Pressure 
ECL   Electrochemiluminescence 
FPI   Fasting Plasma Insulin 
FPG   Fasting Plasma Glucose 
HDL   High Density Lipoproteins 
HOMA  Homeostasis Model Assessment of Insulin Resistance 
LDL   Low Density Lipoproteins 
NPSG   Overnight polysomnography 
RDI   Respiratory Disturbance Index 
SDB   Sleep disordered breathing 
TG   Triglycerides 
TST   Total Sleep Time 
















The prevalence of childhood obesity has reached epidemic proportions worldwide, with rates 
ranging from 7-22% in various countries [1]. In Spain, the enKID study, a cross-sectional 
epidemiological study of a representative sample of the Spanish population aged 2-24 years, 
has clearly established a high frequency of obesity among 6-13 year-old children, as 
evidenced by the 15.6% and 12% rates in boys and girls, respectively [2]. Furthermore, the 
ALADINO study, a community-based cross-sectional study, the aim of which was to 
determine the prevalence of overweight and obese children in Spain, was conducted in 
children aged between 6-9.9 years; the prevalence of obesity was 20.9% in boys and 15.5% in 
girls [3].  
 In this context, pediatric obesity has been recognized as a major medical and public 
health problem because it affects nearly every major organ system [4]. Possible 
complications include insulin resistance, dyslipidemia, and cardiovascular morbidity [4-6]. 
‘Metabolic syndrome’ is a known risk factor for cardiovascular disease in adults, and refers to 
the clustering of insulin resistance, dyslipidemia, hypertension, and obesity. Furthermore, 
when metabolic syndrome occurs during childhood and/or adolescence, it indicates a high 
risk for cardiovascular morbidity during early adulthood [7-9]. 
 Sleep disordered breathing (SDB) is a large group of associated conditions that 
includes habitual snoring, upper airway resistance syndrome, hypoventilation, and obstructive 
sleep apnea syndrome (OSAS), all of which reflect different categories of respiratory 
alteration severity during sleep. Sleep disordered br athing – particularly OSAS – has been 
associated with a large spectrum of neurocognitive, behavioral, cardiovascular, and metabolic 
adverse consequences, the risk of which appears to be particularly exacerbated when 
concurrent obesity is present [10,11]. In recent years, it has become apparent that the risk and 
severity of OSAS are markedly increased by the concurrent presence of obesity [12]. Indeed, 
the prevalence of OSAS in a community-based cohort study in obese children was high, 
ranging from 21.5-39.5% depending on the cut-off and nature of the polysomnographically-
derived respiratory disturbance measures used [13]. 
 Although OSAS in adults has been associated for several decades with increased risk 
for cardiovascular morbidities, it is only more recently that nocturnal elevation of systemic 
blood pressure and sustained diurnal hypertension [14-16], severity-dependent changes in left 
ventricular geometry and function [17], and abnormal endothelial function [18] have emerged 
and been recognized in children with OSAS, along with exacerbated cardiovascular risk, 













cardiometabolic burden that is inherently assignable to OSAS in children, and improved 
understanding of its reversibility would be of clear importance, considering that such 
morbidity is primarily silent in children and usually manifests much later in life, possibly too 
late for corrective measures to be implemented. To better understand the potentially adverse 
contributions of obesity and OSAS to metabolic regulation in children, a prospective study of 
obese children with OSAS and without OSAS was conducted [13,21]. The following analyses 
were performed before and after treatment of OSAS: fasting levels of glucose (Glu), insulin 














Subjects and methods 
A detailed description of the methods pertaining to this cross-sectional, prospective, 
multicenter study has been previously published [13]. Briefly: inclusion criteria were ages 
between 3-14 years, along with a body mass index (BMI) >95th percentile for age and sex, 
and informed consent from parents or legal caretakers (ClinicalTrials.gov Identifier: 
NCT01322763). Consent was routinely obtained from children aged >12 years. The local 
human subject committees of the institutions of the various participating cities in which 
pediatric sleep laboratories were available approved th  study. To guarantee the 
confidentiality of the data, coding of all the data w s performed, such that personal 
information was not available to the investigator-based network. Exclusion criteria were: 
failure to fulfill inclusion criteria, and presence of known genetic syndromes, or any other 
chronic debilitating diseases. All children were obese, and dietary advice and guidance were 
provded to all of them. 
Decisions on the need for treatment of OSAS during the first phase of the study were 
reached by strictly adhering to the Spanish Consensus Criteria, which defined a respiratory 
disturbance index (RDI) ≥3/hour of total sleep time (TST) as the cut-off criterion for 
treatment of OSAS [8]. Based on the polysomnographic findings, four severity-defined 
groups emerged, and were used for follow-up: 
Group 1: No polysomnographic evidence of OSAS (ie, children with RDI <3/hour TST) – no 
treatment was administered. A random sample of 52 children who had an RDI <3/hour TST 
was selected for the follow-up study.  
Group 2: Mild OSAS: children with an RDI ≥3/hour TST but apnea-hypopnea index (AHI) 
<10/hour TST and/or presence of obstructive hypoventilation without significant 
adenotonsillar hypertrophy (0-2 grade of tonsillar hypertrophy and/or adenoid hypertrophy 
<25%). The treatment for this group consisted of supervised dietary modification by a 
clinical nutritionist. 
Group 3: Moderate-severe OSAS: children with an RDI ≥3 and AHI ≥10/hour TST, and/or 
presence of obstructive hypoventilation with significant adenotonsillar hypertrophy (3-4 
grade of tonsillar hypertrophy and/or adenoid hypertrophy >25%) as confirmed by 














Group 4: Moderate-severe OSAS: children with an RDI≥3 and AHI ≥10/hour TST, and/or 
presence of obstructive hypoventilation without nasopharyngoscopic evidence of 
adenotonsillar hypertrophy. The treatment approach in t ese cases consisted of mask fitting 
sessions along with behavioral modification and application of continous positive airway 
pressure (CPAP) treatment after in-laboratory titration.  
 All participants underwent assessment of their medical and sleep history, and were 
subjected to a comprehensive physical examination that included craniofacial evaluation by 
visual inspection, as well as an otolaryngology asses ment that also incorporated an awake 
nasopharyngoscopy under topical sedation. An overnight sleep study (NPSG) in the 
laboratory was then conducted using standard techniques in the presence of one of the 
caretakers throughout the study. Children arrived accompanied by one of their parents to the 
sleep laboratory at approximately 19:30-20:00, and  lights-off routine was implemented at 
21:00, with discontinuation of the sleep recordings at 08:00 the next morning. After removal 
of movement and technical artifacts, the studies were scored according to standard criteria as 
defined by the by the American Academy of Sleep Medicine (AASM) [22]. The proportion 
of time spent in each sleep stage was expressed as percentage of total sleep time (%TST). 
The apnea index (AI) and the AHI were defined as the number of apnea and hypopneas per 
hour of TST. The AHI, obstructive AHI (OAHI), and the RDI were also calculated. The RDI 
was defined as the number of apnea, hypopneas and flow limitations per hour of TST. 
Furthermore, the flow limitation index was calculated based on all events in which flow 
limitation was identified [11,22]. 
Four of the 117 children who completed their designated treatment and follow-up 
protocol did not have blood sampes drawn at follow-up, and were therefore excluded from 
analyses. These four missing cases were evenly distributed across the various groups, and no 
apparent differences in age, sex, RDI, and BMI z-score were present between the missing 
cases and their diagnostic groups. 
 
Metabolic assessments 
 Following the overnight PSG, participants underwent a fasting blood draw. Fasting 
plasma insulin (FPI) levels were measured by electrochemiluminescence (ECL) (Roche 
Cobas 8000 e602; Mannheim, Germany). This assay had a sensitivity of 0.2 uU/mL, linear 













was measured via an enzymatic method with hexokinase (Roche Cobas 8000 c702; 
Mannheim, Germany). This assay had a sensitivity of 2 mg/dL, exhibited a linear range 
between 2-750 mg/dL, and an intra-assay CV ≤1.5%. High-density lipoprotein (HDL), low-
density lipoprotein (LDL), total cholesterol and triglycerides were measured via homogenous 
enzymatic colorimetric assays (Roche Cobas 8000 c702, Mannheim, Germany). The 
analytical measuring ranges and assay coefficients of variations (CV) were:  
 
• Total cholesterol (TChol): range 3.86-800 mg/dL, CV≤1.5% 
• HDL cholesterol: range 3-121 mg/dL, CV ≤1.5% 
• LDL cholesterol: range 3.87-5.49 mg/dL, CV ≤2% 
• Triglycerides (TG): range 8.85-885 mg/dL, CV ≤1.5% 
 
 High-sensitivity CRP levels were determined using a turbidimetric immunoassay 
technique (Roche Cobas 8000 c702, Mannheim, Germany). This assay had a sensitivity of 
0.3 mg/dL, linear range of 0.3-350 mg/L, and intra-assay CV ≤2%. In addition, the 
TChol/HDL, LDL/HDL and TG/HDL ratios were calculated. Higher values denoted greater 
cardiovascular risk [23]. The homeostasis model assessment of insulin resistance (HOMA) 
was calculated as a measure of insulin resistance: [FPI (µIU/mL) * fasting plasma glucose 
(FPG, mg/dL)]/405 [24]; abnormal HOMA values were >3 [25,26]. 
 
Data analysis 
Data were reported as frequency distributions for qualitative variables and 
means±standard deviation for quantitative variables. Comparisons between groups at baseline 
(before treatment) were conducted with t-tests or analysis of variance for quantitative values. 
Comparisons of polysomnographic and demographic chara teristics before and after 
treatment were conducted with paired sample t-tests, or analysis of variance for paired data 
followed by post hoc comparisons (or their corresponding non-parametric tests when the 
conditions of application were not fulfilled), with p-values adjusted for unequal variances, 
when appropriate, after assessment using the Levene’s test for equality of variances, or Chi-
squared analyses for paired data. Spearman´s correlation coefficients were used to examine 
associations between polysomnographic and anthropometric variables and metabolic 













 To analize the changes in metabolic parameters between baseline (T0) and 
follow-up after treatment (T1), general linear models for repeated measures were performed 
using treatment as an independent variable, and age and change in BMI (BMI1-BMI0) as co-
variables, or change in percentile BMI or change in BMI z-score.  
 To examine potential predictors for incidence, persistence or residual OSAS (ie, RDI 
>3/hour TST at follow-up) a general lineal model and logistic regression analysis was 
performed. A two-tailed p-value <0.05 was considered as achieving statistical s gnificance 
and 95% confidence intervals were calculated. All analyses were conducted with the use of 
SPSS software (version 22.0; SPPS Inc., Chicago, Ill.). 
 
Results 
A total of 113 obese children (58 boys, 55 girls) aged 10.3±2.9 and 11.3±2.9 years, 
respectively, at baseline (T0) and follow-up (T1) completed the initial and follow-up 
assessments, including the blood draws within 11.8±4.1 months. Their mean RDI was 
8.6±13.0 at T0 and 3.3±4.0/hour TST at T1 (Wilcoxon test rank: p<0.001). Their mean BMI 














Table 1. Anthropometric characteristics of the study cohort at initial assessment (T0; n= 
113). 
 Anthropometric measures 
Gender Male: 58 (51.3%) 
Female: 55 (48.7%) 
 
 T0 T1 p 
Age (years) 10.35±2.89 11.32±2.85 0.001 
Weight (kg) 59.90±21.01 65.24±21.72 0.001 
Height (m) 1.46±0.18 1.51±0.17  0.001 
BMI (kg/m 2) 27.06±4.05 27.63±4.70 0.070 
BMI percentile 96.84±0.54 95.26±6.73 0.012 
BMI z-score 1.27±0.50 1.34±0.59 0.196 
Neck circumference 
(cm) 
33.82±3.72 33.82±3.42 0.974 
Waist/hip 
circumference 
0.90±0.07 0.88±0.07 0.067 
Systolic BP (mmHg) 103.19±14.32 105.90±12.36 0.038 
Diastolic BP (mmHg) 61.96±10.67 63.10±9.40 0.342 
 















When metabolic parameters between obese children with OSA and without OSAS were 
compared at baseline (T0), only fasting levels of glucose showed statistically significant 
differences (p=0.018) (Table 2).  
 
Primary outcome 
Using a general lineal model for repeated measures, th re were no statistically significant 
differences between baseline T0 and follow-up (T1) in the metabolic parameters for the 
whole cohort, after controlling for age and change in BMI. However, there were statistically 
significant differences in the glucose values betwen surgically treated OSAS (magnitude of 
change: 5.728; p=0.002), CPAP-treated OSAS (magnitude of change: 6.589; p=0.024) when 
compared with the non-OSAS group. There were also statistically significant differences 
between the CPAP-treated OSAS versus non-OSAS group in: CRP (magnitude of change: 
4.528 p=0.036), cholesterol/HDL cholesterol (magnitude of change: 0.917; p=0.008) and 














Table 2. Metabolic values at baseline (T0) in obese children with and without OSAS. 
 OSAS (mean±SD) 
n=62 
Non OSAS (mean±SD) 
n=51 p 
Glucose (mg/dL)  87.77±9.45 83.68±8.33 0.018 
Triglycerides mg/dL 87.41±43.53 79.74±33.61  0.310 
Cholesterol mg/dL 162.34±38.24 168.10±36.68 0.423 
HDL cholesterol mg/dL 47.85±11.56 52.04±11.93 0.064 
LDL cholesterol mg/dL 98.75±29.60 97.98±32.80 0.896 
Cholesterol total/HDL 
cholesterol 
3.55±1.003 3.32±0.77 0.202 
LDL cholesterol/HDL 
cholesterol 
2.16±0.77 1.95±0.70 0.128 
Triglycerides/HDL 
cholesterol 
2.00±1.29 1.67±0.95 0.134 
CRP mg/L 4.71±10.95 2.54±2.60 0.175 
FPI insulin µU/mL 16.82±12.36 15.01±7.61 0.369 
HOMA  3.63±3.006 3.13±1.56 0.300 
 
CRP, C-reactive protein; FPI, fasting plasma insulin; HDL cholesterol, high-density 
lipoprotein; HOMA, homeostasis model assessment of insulin resistance; LDL cholesterol, 















 Using RDI ≥3/hour TST on PSG at follow-up as the criterion for the presence of 
OSAS, the study found that in Group 1, 41 (78.8%) of the children remained with an RDI 
<3/hour TST at T1 (no OSAS), while 11 (21.2%) evolved into RDI ≥3/hour TST at T1 
(incident cases). In Group 2, 18 (50%) subjects remained with an RDI ≥3/hour TST at T1 
(persistent cases) and in the other 18 (50%), nutritional intervention resulted in a RDI 
<3/hour TST at T1 (remission cases). In Group 3, 10 (43.5%) children remained with an RDI 
≥3/hour TST at T1 (residual cases), while 13 (56.5%) had an RDI <3/hour TST at T1 
(resolved cases). In Group 4, one (16.6%) remained with an RDI ≥3/hour TST at T1 (residual 
case), while five (83.3%) had an RDI <3/hour TST at 1 (controlled cases). The findings for 
age, sex, RDI, AHI, BMI and BMI z-score of the eight groups at follow-up are shown in 

















Table 3. Characteristics of the cohort at follow-up (T1) according to diagnosis at T0 (n=113).  
  Sex M/F Age RDI AHI BMI BMI1-
BMI0 
BMI 
 Non OSAS 
Non OSAS 
n=40 
T0 21/19 10.2±2.7 1.4±0.8 0.5±0.5 25.8±3.2 0.4±2.4 –0.45±0.7
T1 11.1±2.6 0.9±0.7 0.4±0.4 26.2±3.9 –0.29±0.8
Incident cases 
n=11 
T0 7/4 10.8±2.8 1.8±0.9 0.8±0.8 27.9±4.1 0.4±2.1 –0.01±0.8
T1 11.6±2.6 7.2±2.8 4.1±2.1 28.4±5.4 0.15±1.1
 Mild OSAS 
Remission 
cases n=17 
T0 7/10 11.1±2.3 5.9±2.2 2.6±1.6 27.8±4.1 –0.3±2.8 –
T1 12.2±2.4 1.7±0.9 0.6±0.6 27.5±5.0 0.003±1.0
Persistent cases 
n=18 
T0 8/10 11.4±2.1 11.2±6.3 4.5±5.2 27.9±3.0 0.4±2.1 –
T1 12.2±2.2 7.7±5.5 3.9±3.5 28.3±4.0 0.14±0.8
  Moderate-severe surgically treated OSAS 
Resolved cases 
n=12 
T0 5/7 8.3±3.9 20.6±24.2 13.9±23.9 26.2±5.2 0.2±3.8 –0.31±1.1
T1 9.6±3.7 1.2±0.9 0.4±0.5 26.4±3.1 –0.26±0.7
Residual cases 
n=9 
T0 5/4 9.4±3.4 16.7±14.2 12.9±13.7 25.9±3.9 1.8±1.5 –0.52±0.8
T1 10.4±3.6 6.7±3.2 2.6±3.2 27.7±4.9 –0.06±1.1
  Moderate-severe CPAP-treated OSAS 
Resolved cases 
n=5 
T0 2/3 11.2±2.2 28.1±19.8 24.9±19.9 33.3±3.5 1.9±1.7 1.12±0.7
T1 11.8±2.2 0.4±0.2 0.1±0.2 35.2±3.9 1.61±0.8
Residual cases 
n=1 
T0 1/0 15.0± 40.0 39.8 40.1 –0.7± 2.57±
T1 16.5± 14.7 11.8 39.4 2.49±
AHI, apnea-hypopnea index; BMI z-score, body mass index z-score; BMI, body mass index; 














 Changes in metabolic parameters according to sub-group categories at follow-up are 
shown in Table 4 and Table 5. In general, there were no significant changes in blood-based 
measures for the whole cohort. However, several significant changes occurred in the sub-
group analyses after treatment. Indeed, among children undergoing T&A, HDL cholesterol 
was significantly higher, and triglycerides, total cholesterol/HDL, LDL/HDL, triglycerides/ 
HDL cholesterol ratios were all significantly lower at T1, indicating more favorable 
lipoprotein profiles in the group of children in whom T&A successfully normalized 
polysomnographically-recorded respiratory measures.  
 In the non-OSAS group, CRP levels decreased at T1, whereas the levels increased in 
the incident group. Similarly, CRP levels decreased in the remission group and increased in 
the persistent group. Regarding the surgically treated group, the children in the residual group 
presented higher plasma levels of CRP when compared with the surgically resolved group. 
The highest levels of CRP emerging among the group of children treated with CPAP with 














Table 4. Metabolic values at baseline (T0) and follow-up (T1) in children initially included 
in Groups 1 and 2. 




























T0 83.9±7.4 82.6±11.3 84.4±9.2 87.7±7.9 
T1 84.7±6.7 87.6±8.9 88.0±8.9 84.3±6.0* 
Triglycerides 
mg/dL 
T0 79.7±35.6 80.0±26.9 83.8±42.4 83.7±46.8 
T1 78.7±37.7 67.2±25.1* 79.4±34.7 85.2±50.8 
Cholesterol 
mg/dL 
T0 172.9±4 151.0±26.3 162.2±37.4 156.4±42.2 




T0 53.5±11.8 46.8±11.3 46.1±10.4 49.9±11.5 




T0 100.7±35.1 88.3±21.6 99.3±28.6 95.8±27.5 




T0 3.3±0.8 3.3±0.6 3.6±0.9 3.3±1.1 





T0 1.9±0.7 1.9±0.5 2.2±0.7 2.0±0.2 




T0 1.6±0.9 1.9±1.1 1.9±1.1 1.8±0.3 
T1 1.6±0.9 1.5±1.0* 1.9±0.9 2.0±0.3 
CRP mg/L T0 2.5±2.7 2.7±2.1 6.7±20.3 4.0±4.9 















T0 14.7±7.9 16.0±6.8 17.4±10.4 20.8±18.0 
T1 15.9±7.5 17.3±8.2 20.5±12.4 18.9±8.3 
HOMA 3.1±1.7 3.2±1.2 3.3±1.9 4.8±5.1 
T1 3.4±1.7 3.8±2.3 4.3±2.4 3.9±1.8 
*  p<0.05 
CRP, C-reactive protein; FPI, fasting plasma insulin; HDL cholesterol, high-density 
lipoprotein; HOMA, homeostasis model assessment of insulin resistance; LDL cholesterol, 















Table 5. Metabolic values at baseline (T0) and follow-up (T1) in children initially included 
in Groups 3 and 4.  





































mg/dL    
T0 90.5±9.9 87.4±6.6 87.2±7.4 120.0± 
T1 89.0±7.8 92.1±7.4 89.4±2.9 95± 
Triglycerides 
mg/dL   
T0 87.2±41.9 79.0±45.0 109.8±29.7 172.0± 
T1 69.8±27.7* 98.6±56.0 92.0±31.3 81.0± 
Cholesterol 
mg/dL   
 
T0 156.0±18.82 162.50±35.59 171.20±19.79 301.0± 
T1 159.2±29.1 164.5±23.1 177.2±23.2 182.0± 
HDL 
cholesterol 
mg/dL    
T0 48.7±14.9 49.1±12.2 43.0±8.1 43.0± 




T0 89.9±15.0 97.4±27.6 106.0±20.6 224.0± 




T0 3.4±0.8 3.4 ±0.7 4.1 ±0.7 7.0± 





T0 1.9±0.6 2.0±0.6 2.5±0.6 5.2± 




T0 2.1±1.7 1.7±1.2 2.6±0.9 4.0± 













CRP mg/L    T0 2.0±1.6 4.2±4.7 8.6±8.2 4.0± 
T1 2.5±2.7 4.2±6.1 5.4±3.4 4.0 ± 
Insulin 
µU/mL     
T0 12.3 ±6.5 14.7 ±6.6 15.6±4.5 12.0 ± 
T1 15.9±10.2 16.5 ±6.6 24.6±13.5 23.5 ± 
HOMA T0 2.8 ±1.6 3.1±1.3 3.4±1.2 3.6 ± 
T1 3.6±2.7 3.8±1.7 5.4±2.9 5.5 ± 
 
* p<0.05 
CRP, C-reactive protein; FPI, fasting plasma insulin; HDL cholesterol, high-density 
lipoprotein; HOMA, homeostasis model assessment of insulin resistance; LDL cholesterol, 

















Statistically significant correlations are shown in Table 6 and Table 7. For the total cohort, 
BMI z-score was associated with triglycerides, CRP, FPI and HOMA at T0, and these 
associations persisted at T1. Analyses of follow-up groups revealed that BMI was positively 
correlated with CRP in the persistent group, and with FPI and HOMA in the non-OSAS, 














Table 6. Statistically significant correlations between metabolic variables and BMI or 
































0.314**        
CRP mg/L 0.183*    0.499*    
FPI (insulin) 
µU/mL     
0.468* *  0.368*  0.665**  0.699*   0.900* 
HOMA 0.436**  0.309*  0.577* 
 
 0.657*   0.900* 
RDI 
Glucose mg/dL 0.237*        
Triglycerides 
mg/dL 
     0.606*    
HDL cholesterol 
mg/dL 
–0.245**     –0.678*    
AHI 
Glucose mg/dL 0.203*        
Triglycerides 
mg/dL 
     0.774**    
HDL cholesterol 
mg/dL 
–0.337**     -0.853**   
Arousals index 
Glucose mg/dL 0.346**   0.733* 
 















     0.708*    
FPI (insulin) 
µU/mL     
0.216*        
HOMA  0.258**      0.594*   
Desaturation index 
Glucose mg/dL  0.341*       
*p<0.05 
** p<0.001 
AHI, apnea-hypopnea index; BMI, body mass index; CRP, C-reactive protein; FPI, fasting 
plasma insulin; HDL cholesterol, high-density lipopr tein; HOMA, homeostasis model 
assessment of insulin resistance; LDL cholesterol, low-density lipoprotein; RDI, respiratory 















Table 7. Statistically significant correlations between metabolic variables and BMI or 
polysomnographic measures at T1. 
























Glucose mg/dL 0.245*  0.332*      
Triglycerides 
mg/dL 
0.310*       
Cholesterol 
mg/dL 







     
LDL cholesterol 
mg/dL 





0.183*       
FPI (insulin) 
µU/mL     
0.572**  0.580** 
 
 0.738**  0.564*   0.762*  




0.237*   0.772**  
 





     
HDL cholesterol 
mg/dL 
–0.245**        
Insulin    0.609* 
 
    
HOMA    0.682* 
 
















–0.256**        
Desaturation index 
Glucose mg/dL      0.695*  
 
 
CRP mg/L 0.248**  
 
  0.727**     
*p<0.05 
** p< 0.001 
AHI, apnea-hypopnea index; BMI, body mass index; CRP, C-reactive protein; FPI, fasting 
plasma insulin; HDL cholesterol, high-density lipopr tein; HOMA, Homeostasis Model 
Assessment of Insulin Resistance; LDL cholesterol, low density lipoprotein; RDI, 















 RDI and AHI were positively associated with fasting glycemic levels in the whole 
cohort, and were also significantly correlated with triglyceride levels in the surgically 
resolved group, and negatively correlated with HDL cholesterol levels in both the whole 
cohort, and the surgically resolved group at T0. In addition, the arousal index was positively 
associated with fasting glucose levels in the whole c hort, as well as in the incident and 
surgically resolved groups, and with HOMA in the total cohort and the surgically resolved 
group at T0. Finally, the oxygen desaturation index was positively correlated with glucose 
levels in the whole cohort at T0. Correlations between sleep and metabolic parameters 
persisted after controlling for BMI.  
 
Predictors of incidence, persistence and residual OSAS 
The study examined the associations between age, BMI and metabolic parameters and RDI at 
follow-up to explore whether any baseline variable could predict post-intervention OSAS. 
Although multiple factors showed statistical trends in the stepwise regression analyses, there 
were no significant predictors that would have reliably identified OSAS at T1. Of all the 
variables analyzed, statistical trends that emerged were as follows: HOMA appeared to be 
associated with increased risk for incident OSAS (OR: 1.97; 95% CI: 0.18-21.27, p=0.057) 
and persistent OSAS (OR: 1.10; 95% CI: 0.04-27.77, p=0.953), while CRP levels trended to 




General linear model of OSA treated  
In order to assess the effects of OSAS treatment on the metabolic and inflammatory profiles, 
a general linear model of repeated measures before and after treatment was performed. For 
this analysis, the non-OSAS group was excluded from the analysis and those who underwent 
surgical or CP P treatment (n=27) were compared to those who only received dietary 
treatment (n=35), while adjusting for the BMI percentile. In these analyses, statistically 
significant differences were observed only in glucose values (p=0.037). 
General linear model persistent OSAS versus resolved OSAS 
To assess the effect of treatment on the metabolic and inflammatory profile, a general linear 













OSAS (n=28) versus resolved OSAS (n=34), while controlling for percentile BMI. Although 
these analyses showed a trend toward improvements in metabolic and inflammatory 
parameters in the resolved OSAS group when compared with persistent OSAS, there were no 
significant differences in any of the analyzed parameters.  
Pubertal status 
The aforementioned analyses were not performed while adjusting for pubertal state. 
However, to avoid the confounding effect of puberty on the metabolic profile, an analysis 
was performed dividing the population of study according to age: children younger or older 
than 9 years of age. A general linear model of repeated measures before and after treatment 
that controlled for the dichotomized age and the change in BMI z-score was used to assess 
the effect of treatment on the metabolic and inflammatory profile. Significant effects of the 
treatment emerged on glucose profile (p=0.003), cholesterol total/ HDL ratio (p=0.044), LDL 
cholesterol/HDL cholesterol ratio (p=0.019) and CRP (p=0.023), regardless of age stratum 















This study prospectively assessed the impact of various treatment modalities on metabolic 
profiles in a community-based cohort of obese children, in whom their primary care 
physicians diagnosed obesity. The high prevalence of both snoring and OSAS in otherwise 
‘healthy’ obese children has previously been described [13]. The second phase of the study, 
which focused around treatment outcomes [21] that were further confirmed in the present 
study, revealed that T&A improved HDL cholesterol and triglyceride levels, suggesting that 
OSAS could be involved in creating an adverse metabolic state independent from obesity. 
The present study reported on the findings that HOMA showed statistical trends as a 
predictor of incidence and persistence of OSAS, suggesting that if obese children present 
evidence of insulin resistance, the likelihood of underlying OSAS is markedly greater. 
However, it should be noted that the relatively lownumber of cases in each of the eight sub-
groups did not allow for definitive conclusions. Furthermore, the observations showing that 
CRP levels increased in both the incident and persist nt groups at T1, as well as the presence 
of higher CRP levels in children with residual OSAS when compared with the surgically 
resolved group, suggest that CRP may provide value as an adjunt biomarker of risk for the 
presence of OSAS during prospective follow-up [27]. The diferences between treated groups 
compared with the non-OSAS group further reinforce the effect of treatment on metabolic 
and inflammatory parameters. Indeed, in this prospectiv  study it was found that serum lipid 
profiles were significantly improved after T&A in the group of children with moderate-severe 
OSAS whose sleep-disordered breathing was completely resolved and resulted in 
normalization of their PSG. In contrast, no lipid profile improvements occurred in the 
surgically treated group whose post-treatment PSG attested to the continued presence of 
OSAS. These findings support the contention that OSAS, at least among obese children, 
independently and adversely alters the lipid profile, and thus confers increased cardiovascular 
risk. These results are also in close agreement with those reported recently in a cohort of 69 
children with OSAS (mean age: 5.9 years (range 3-16), 68% non-obese) who underwent 
T&A for OSAS treatment, whereby HDL cholesterol levels improved significantly after 
surgery [28]. However, since the present study exclusively involved obese children, the 
current findings further emphasize the association of OSAS with cardiovascular risk. 
 Perusal of the several pediatric studies that explored the impact of OSAS on metabolic 
function yields contradictory findings; while some of the studies reported significant 













no independent associations [29-32]. In addition to these association studies, those studies 
that have examined the effect of OSAS treatment upon metabolic measures in children have 
been similarly contradictory. For example, the only randomized multicenter trial of T&A in 
children found no improvements in circulating lipopr teins, or in any other cardiometabolic 
markers in children aged 5-9 years with OSAS undergoing T&A [33]. Similarly, Apostolidou 
and colleagues assessed the effect of adenoidectomy and/or tonsilectomy on serum markers 
of inflammation and on fasting insulin levels in 58 children with OSAS and 17 controls, and 
found no improvements in insulin resistance [34]. In contrast, an earlier study on 62 children 
with OSAS (35 obese and 25 non-obese) reported T&A-associated improvements in total 
cholesterol, HDL, and LDL among all children, but improvements in triglycerides and insulin 
resistance were exclusively restricted to obese children [35]. In a cohort of 459 children aged 
5-12 years, obesity was the primary driver of most associations between OSA and metabolic 
measures [36]. It should be pointed out that the age cut-off of the aforementioned studies was 
younger than in the present study, and it is likely that younger children may be less prone to 
developing signifcant metabolic changes in the context of OSAS. Indeed, studies in 
adolescents have found associations between OSAS and insulin resistance measures 
independent of obesity [29,30,37], and the present study would seem to further indicate that 
effective treatment of OSAS would ameliorate insulin resistance when the latter is present.  
 Few studies have evaluated the effects of weight loss on metabolic profile in obese 
OSAS children. One study of obese adolescents with a mean age of 15.5 years performed an 
inpatient-based dietary intervention for weight loss in 50 patients. Except for glycemic 
values, all parameters improved significantly after w ight loss, both for patients with and 
without OSAS, and HDL cholesterol improved proportionaly with the decrease in BMI-z-
score [38]. In the present study, the group of children with mild OSAS who underwent only 
dietary treatment did not show evidence of significant changes in metabolic parameters at 
follow-up. However, such children were younger and less obese than the children included in 
the study by Hoorenbeeck and colleagues [38]. The present subgroup analyses at follow-up 
further reinforce the putative effect of OSAS on insulin resistance; an effect that appears to 
be superimposed on the independent effect of obesity on insulin resistance. 
C-reactive protein (CRP) levels have been shown to be increased in the presence of obesity in 
children [39], and CRP is a significant inflammatory mediator and independent marker of 
cardiovascular disease [40]. It is produced in the liver, and is thought to actively participate in 













molecules [41]. The association between CRP concentrations and pediatric OSAS has now 
been inferred from a large body of work that generally indicates, albeit with some notable 
exceptions that may be explained by genetic and environmental interactions [42,43], the 
presence of increased circulating levels of CRP with increasing severity of OSAS [44]. 
Furthermore, a recent meta-analysis that included eight original studies came to the 
conclusion that T&A significantly reduces CRP levels in children with OSAS [45]. Thus, 
CRP has emerged as a potentially useful biomarker of OSAS-mediated end-organ morbidity, 
including the ability to identify children who are at increased risk of adverse neurocognitive 
functioning [46]. Additionally, in a recent multicenter study conducted in four European and 
US pediatric sleep centers, which included 182 children with OSAS treated with T&A, the 
presence of residual moderate-severe OSAS following sur ery (post T&A AHI >5/hour TST) 
exhibited significantly higher CRP levels when compared with those children in whom T&A 
led to resolved OSAS (ie, post T&A AHI <1.5/hour TST) [27]. In the present study, CRP 
levels decreased at follow-up in the non-OSAS and remission groups, whereas levels 
increased in the incident and persistent groups. Furthermore, those children with residual 
OSAS in the surgically treated group also presented higher CRP levels when compared with 
the surgically resolved group, with the highest leve s of CRP being observed in the group of 
children treated with CPAP. Therefore, it is believed that additional studies will be needed to 
show the usefulness of CRP as a longitudinal biomarker of OSAS [47-49]. 
 Some methodological issues and limitations of the present study deserve comment. 
First, the prospectively designed recruitment of the cohort was based on the diagnosis of 
obesity during routine well-child visits by pediatrcians in the community, thereby obviating 
any potential a priori selection bias. Consequently, one of the study subjects had been 
previously evaluated for snoring, or had been clinially suspected or treated for OSAS. Based 
on their initial PSG findings, four groups were defin d for intervention (non-treatment, 
dietary treatment, surgical treatment and CPAP treatm nt), and therefore eight groups 
emerged in the follow-up assessments (using the dichotomous variable of OSAS present or 
absent), resulting in substantial fragmentation of the cohort at follow-up into small cell 
numbers. It is believed that this is the first study to examine different treatment approaches 
according to the severity of OSAS. Although this obvi usly constitutes strength of the study, 
it imposes the presence of smaller sample sizes for each of the subgroups studied, and their 
potential for inducing a beta 2 error. However, the total follow-up sample consisted of 113 
obese children, which is the largest obese cohort studied thus far in a prospective fashion. 













of insulin resistance and dyslipidemia, given the inclusion of both pre-pubertal and pubertal 
children. To attempt and reduce this limitation, an analysis was preformed to divide the study 
population into children aged <9 years and >9 years, and the findings remained unchanged. 
Taken together, the current findings provide a strong incentive for a large, prospective 
interventional study that enables a clearer and more definitive set of conclusions.  
 In summary, effective treatment of OSAS improved lipid profiles and insulin 
resistance in obese children when such abnormalities in metabolic function were present. 
Furthermore, CRP levels appeared to be useful for potentially predicting follow-up status 
regarding OSAS, particularly in obese children in whom a very high proportion was likely to 
manifest persistence of their sleep-disordered breating fter treatment. However, additional 
multicenter studies will be necessary to confirm these preliminary observations. Finally, 
HOMA values were associated with incidence or persistence of OSAS, suggesting that 
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• In obese children with obstructive sleep apnea syndrome (OSAS) the impact of treatment 
on metabolic function is unclear.  
• Effective treatment of OSAS improves lipid profiles in obese children from the 
community. 
• Effective treatment of OSAS could improve glucose metabolism in obese children with 
OSAS from the community. 
 
